Since Celastrol is also known to target the MyBP-C (96), perhaps further research into the mechanism by which this targeting occurs could reveal Celastrol as a therapeutic target in lowering the (oxidised) tetrahydrobiopterin-mediated cardiac dysfunction, when subjected to hypertension-induced oxidative stress. The gene discussed is MYBPC3; the disease is hypertensive disorder.